<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03810443</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180352</org_study_id>
    <nct_id>NCT03810443</nct_id>
  </id_info>
  <brief_title>Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension</brief_title>
  <acronym>HYPER2</acronym>
  <official_title>Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same&#xD;
      haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension.&#xD;
      The hyperventilation syndrome is a frequent cause of dyspnea in general population and in&#xD;
      respiratory diseases like asthma but has never been studied in pulmonary hypertension. The&#xD;
      goal of this study is to measure the prevalence of pulmonary hypertension in a population of&#xD;
      patients with controlled pulmonary arterial hypertension (PAH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperventilation syndrome has been described as a cause of dyspnea in the general population&#xD;
      and in several chronic respiratory diseases such as asthma with 20 to 40% of asthmatics&#xD;
      affected. However, Hyperventilation syndrome has never been sought in a population with PAH.&#xD;
      Hyperventilation syndrome, although complex pathophysiology, may be simply corrected by a&#xD;
      management of respiratory physiotherapy based on the control of respiration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 14, 2019</start_date>
  <completion_date type="Anticipated">July 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of the hyperventilation syndrome</measure>
    <time_frame>18 months</time_frame>
    <description>Prevalence of the hyperventilation syndrome in a population with pulmonary arterial hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anxiety-depression questionary score</measure>
    <time_frame>18 months</time_frame>
    <description>results of anxiety-depression questionary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyspnea score</measure>
    <time_frame>18 months</time_frame>
    <description>results of dyspnea questionary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>18 months</time_frame>
    <description>results of quality of life questionary</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>pulmonary arterial hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hyperventilation test</intervention_name>
    <description>The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.</description>
    <arm_group_label>pulmonary arterial hypertension</arm_group_label>
    <other_name>Questionnaire of Nijmegen</other_name>
    <other_name>Questionnaire of Dyspnea</other_name>
    <other_name>Questionnaire of quality of life</other_name>
    <other_name>Questionnaire of screening for psychological disorders</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non smoker or tobacco stopped for minimum 2 years ans maximum 10 year-pack. -&#xD;
             Idiopathic, heritable, related to drug or toxics, associated with controlled pulmonary&#xD;
             hypertension. Diagnosis and treatment of pulmonary hypertension for more than 4&#xD;
             months.&#xD;
&#xD;
          -  Optimal control of pulmonary hypertension (no right heart failure symptom and NTproBNP&#xD;
             &lt; 300ng/L or Brain Natriuretic Peptide(BNP) &lt; 50 ng/L and optimal hemodynamic results&#xD;
             measured by a right heart catheterization in the last year: right atrial pressure &lt; 8&#xD;
             mmHg, cardiac index &gt; 2,5 L/min/m2, veinous saturation in oxygen &gt; 65%)&#xD;
&#xD;
          -  Informed and written consent&#xD;
&#xD;
          -  Non-affiliation to a social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Existence of another form of pulmonary hypertension&#xD;
&#xD;
          -  Existence of vocal cord dysfunction&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Obesity&gt; stage 2 (BMI 35 kg / m2)&#xD;
&#xD;
          -  Age ≥ 75 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne-Marie JUTANT, CCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Etienne-Marie JUTANT, CCA</last_name>
    <phone>01 45 21 78 91</phone>
    <email>etiennemarie.jutant@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Bicêtre - Pneumology department</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Etienne-Marie JUTANT, CCA</last_name>
      <phone>01 45 21 78 91</phone>
      <email>etiennemarie.jutant@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hyperventilation</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

